Portage Biotech Inc. (NASDAQ:PRTG) Sees Large Decline in Short Interest

Portage Biotech Inc. (NASDAQ:PRTG) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 14,000 shares, a decline of 74.5% from the June 15th total of 54,900 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 732,100 shares, the days-to-cover ratio is presently 0.0 days.

Portage Biotech Price Performance

Shares of NASDAQ:PRTG remained flat at $0.18 during midday trading on Friday. The stock had a trading volume of 562,441 shares, compared to its average volume of 398,872. Portage Biotech has a 52-week low of $0.13 and a 52-week high of $3.60. The business has a 50-day simple moving average of $0.25 and a two-hundred day simple moving average of $0.55. The firm has a market cap of $3.19 million, a P/E ratio of -0.02 and a beta of 1.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.78 and a current ratio of 2.78.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.